UK markets closed
  • NIKKEI 225

    -180.63 (-0.65%)

    +471.59 (+2.40%)

    -0.23 (-0.24%)

    -2.90 (-0.16%)
  • DOW

    +27.16 (+0.08%)

    +58.08 (+0.29%)
  • CMC Crypto 200

    -1.61 (-0.28%)
  • ^IXIC

    -74.89 (-0.58%)
  • ^FTAS

    -19.42 (-0.47%)

Subcutaneous Immunoglobulin (SCIg) Market Report Comparison by Rating, ToC, Page Count, and Price only at Douglas Insights

·4-min read
Douglas Insights
Douglas Insights

Major countries covered in the Subcutaneous Immunoglobulin (SCIg) Market report include Germany, UK, France, Italy, Spain, Russia, U.S., Canada, Mexico, Brazil, Argentina, China, Japan, India, South Korea, Israel, GCC countries, South Africa, Turkey, etc.

Isle of Man, UK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- What is Subcutaneous Immunoglobulin (SCIg)?

The growing interest in subcutaneous administration, a method of injecting immunoglobulin through the skin, has been observed in recent years (subcutaneous immunoglobulin, or SCIg). Patients with immunodeficiency frequently use SCIg. Patients administer SCIg to themselves at home. Infusions are typically administered to the thighs or stomach fat beneath the skin. Small studies of SCIg in patients with CIDP have been conducted over the past few years. It has become a well-liked method of treating CIDP patients in Europe and the United States. Many different IVIg brands can be administered subcutaneously, but only a few products are designed for this method.

Subcutaneously administered immunoglobulin provides more stable serum immunoglobulin levels and has a lower incidence of systemic adverse effects than the intravenous route. This method increases the quality of the patient’s life by self administration or parental administration at home. Immunoglobulin preparations designed for subcutaneous administration have been available in Europe and the US since 2006. Although subcutaneous immunoglobulin preparations are not available in Turkey, the subcutaneous administration route has recently been included in the instructions of the three intravenous products with 10% concentration.

Compare the report by table of contents, price, number of pages, Publisher rating and published date -

About Subcutaneous Immunoglobulin (SCIg) Market Growth

The steady increase in the use of intravenous immunoglobulin for the treatment of off-label indications is expected to drive the market during the forecast period. Common off-label indications treated with intravenous immunoglobulin are Guillain-Barre syndrome, multifocal motor neuropathy, dermatomyositis, polymyositis, stiff person syndrome, and relapsing-remitting multiple sclerosis.

New technologies in manufacturing and purifying intravenous and subcutaneous immunoglobulin (SCIG) have made these safer and free from protein, viral, or other contaminants. This has increased clinician preference for the use of intravenous immunoglobulin. This in turn is expected to boost demand for SCIG.

Subcutaneous Immunoglobulin (SCIg) Market Segmentation

The market is segmented based on application, end-user, and geography. Application-wise, the global subcutaneous immunoglobulin market is segmented into secondary immunodeficiency diseases, primary immunodeficiency diseases and other diseases. Furthermore, the global subcutaneous immunoglobulin market is geographically segmented into North America, South America, Europe, and Asia Pacific. Other segments include neurological disorders, infectious diseases and bleeding disorders etc.

A tool for comparing research reports for subcutaneous immunoglobulin has been released by Douglas Insights. By providing access to all digital market reports on Subcutaneous Immunoglobulin (SCIg) market trends, size, and growth patterns, Douglas Insights' most recent addition to the world's first comparison engine enables users to find the most recent, highly regarded, thorough, pertinent, and reasonably priced publications. In addition, the tool enables the comparison of up to three market reports simultaneously. The main comparison criteria are publisher Rating, Table of Contents, Page Count, and Price.

Top Key Players Covered in Reports

  • Biotest AG

  • CSL Limited

  • Grifols SA

  • Kedrion S.p.A

  • Octapharma AG

  • Takeda Pharmaceutical Company Limited (Shire)

  • Bio Products Laboratory Ltd.

  • LFB S.A

The report offers:

  • The top geographical end-users of subcutaneous immunoglobulin, including regions where the industry is expanding or intends to launch a product.

  • The current trends in the subcutaneous immunoglobulin market.

  • Market sizing for the global subcutaneous immunoglobulin market from 2015 to 2027, quantifying market growth during the forecast period.

  • Player mapping that takes into account the products and services offered, business strengths, strategic initiatives, product launches, geographical expansion and player profiling.

Compare now-

Frequently Asked Questions

Que- Can i create custom Project on Subcutaneous Immunoglobulin Market?

Ans- Yes you can create custom project on Subcutaneous Immunoglobulin Market based on your budget and scope.

Que- How to Compare Table of Contents of Subcutaneous Immunoglobulin Market Reports?

Ans- You can select three reports on Subcutaneous Immunoglobulin Market to compare Table of Contents.

Que- How to find best report on Subcutaneous Immunoglobulin Market?

Ans- You can compare Subcutaneous Immunoglobulin Market Reports by table of contents, price, number of pages, Publisher rating and published date. it will help you to finalize best report on Subcutaneous Immunoglobulin Market.

About Douglas Insights:

Douglas Insights UK limited is first company to provide comparison of market research reports by Table of content, price, ratings and number of pages. We understand the value of time. Productivity and efficiency are possible when you take prompt and assured decisions.

Related Comparisions:

Subcutaneous Drug Delivery Market :

Subcutaneous Biologics Market :

Compare Reports on Subcutaneous Immunoglobulin Market by Price, Table of Contents, Number of pages and Publisher ratings - Douglas Insights

CONTACT: Office- Bridge House, W Baldwin Rd, Isle of Man IM4 5HA, Isle of Man Email- Telephone - +44 7624 248772 Web-

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting